Genetic Polymorphisms in Pharmaceuticals and Chemotherapy
Open Access
- 1 October 2021
- journal article
- review article
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 12 (5) , 149-154
Abstract
Genetic Polymorphisms in Pharmaceuticals and ChemotherapyKeywords
This publication has 34 references indexed in Scilit:
- Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol TartrateClinical Pharmacology & Therapeutics, 2014
- Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized TherapyPLOS ONE, 2013
- Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic AberrationsPLOS ONE, 2013
- Ivacaftor: A Novel Gene-Based Therapeutic Approach for Cystic FibrosisThe Journal of Pediatric Pharmacology and Therapeutics, 2013
- Association Analysis of CYP2A6 Genotypes and Haplotypes with 5-Fluorouracil Formation from Tegafur in Human Liver MicrosomesPharmacogenomics, 2011
- Gene copy-number polymorphism in natureProceedings Of The Royal Society B-Biological Sciences, 2010
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Nature Reviews Neurology, 2009
- A Brief Review of Short Tandem Repeat MutationGenomics, Proteomics & Bioinformatics, 2007
- Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityThe Pharmacogenomics Journal, 2004
- ADVERSE EFFECTS OF DAPSONEInternational Journal of Dermatology, 1975